Papillary Thyroid Cancer - Pipeline Review, H1 2015


#284273

105pages

Global Markets Direct

$ 2000

In Stock



Global Markets Directs, Papillary Thyroid Cancer Pipeline Review, H1 2015, provides an overview of the Papillary Thyroid Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Papillary Thyroid Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Papillary Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Papillary Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Papillary Thyroid Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Papillary Thyroid Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Papillary Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Papillary Thyroid Cancer - Overview 8
Pipeline Products for Papillary Thyroid Cancer - Comparative Analysis 9
Papillary Thyroid Cancer - Therapeutics under Development by Companies 10
Papillary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Papillary Thyroid Cancer - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Papillary Thyroid Cancer - Products under Development by Companies 15
Papillary Thyroid Cancer - Products under Investigation by Universities/Institutes 16
Papillary Thyroid Cancer - Companies Involved in Therapeutics Development 17
AstraZeneca PLC 17
Eisai Co., Ltd. 18
Exelixis, Inc. 19
Ignyta, Inc. 20
Novartis AG 21
Pfizer Inc. 22
Plexxikon Inc. 23
Vaccinex, Inc. 24
Papillary Thyroid Cancer - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
cabozantinib s-malate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CLM-29 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CLM-3 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dabrafenib mesylate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
entrectinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
everolimus - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
lenvatinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
pasireotide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PLX-7486 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
PLX-8394 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
sunitinib malate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
vandetanib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
VX-15 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Papillary Thyroid Cancer - Recent Pipeline Updates 71
Papillary Thyroid Cancer - Dormant Projects 100
Papillary Thyroid Cancer - Discontinued Products 101
Papillary Thyroid Cancer - Product Development Milestones 102
Featured News & Press Releases 102
May 06, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains European Orphan Drug Status 102
Feb 14, 2013: Eisai's Thyroid Cancer Drug Candidate Lenvatinib Obtains FDA Orphan Drug Status 102
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 102

Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 104
Disclaimer 105

Number of Products under Development for Papillary Thyroid Cancer, H1 2015 8
Number of Products under Development for Papillary Thyroid Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Papillary Thyroid Cancer - Pipeline by AstraZeneca PLC, H1 2015 17
Papillary Thyroid Cancer - Pipeline by Eisai Co., Ltd., H1 2015 18
Papillary Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2015 19
Papillary Thyroid Cancer - Pipeline by Ignyta, Inc., H1 2015 20
Papillary Thyroid Cancer - Pipeline by Novartis AG, H1 2015 21
Papillary Thyroid Cancer - Pipeline by Pfizer Inc., H1 2015 22
Papillary Thyroid Cancer - Pipeline by Plexxikon Inc., H1 2015 23
Papillary Thyroid Cancer - Pipeline by Vaccinex, Inc., H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Papillary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2015 71
Papillary Thyroid Cancer - Dormant Projects, H1 2015 100
Papillary Thyroid Cancer - Discontinued Products, H1 2015 101

Number of Products under Development for Papillary Thyroid Cancer, H1 2015 8
Number of Products under Development for Papillary Thyroid Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Top 10 Targets, H1 2015 26
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
Number of Products by Top 10 Routes of Administration, H1 2015 31
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32
Number of Products by Top 10 Molecule Types, H1 2015 33
Number of Products by Stage and Top 10 Molecule Types, H1 2015 34